ABBOTT INDIA
Quarterly Results Analysis [Dec2024]
ABBOTT INDIA Quarterly Results
Standalone | Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,614 Cr | ₹1,633 Cr | ₹1,558 Cr | ₹1,439 Cr | ₹1,437 Cr | ₹1,494 Cr | ₹1,479 Cr | ₹1,343 Cr |
Expenses | ₹1,178 Cr | ₹1,194 Cr | ₹1,167 Cr | ₹1,109 Cr | ₹1,049 Cr | ₹1,113 Cr | ₹1,124 Cr | ₹1,063 Cr |
Operating Income | ₹436 Cr | ₹439 Cr | ₹391 Cr | ₹330 Cr | ₹388 Cr | ₹381 Cr | ₹355 Cr | ₹280 Cr |
Other Income | ₹72 Cr | ₹60 Cr | ₹67 Cr | ₹81 Cr | ₹56 Cr | ₹56 Cr | ₹56 Cr | ₹50 Cr |
Interest | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr |
Depreciation | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹17 Cr | ₹17 Cr |
Profit Before Tax | ₹488 Cr | ₹479 Cr | ₹437 Cr | ₹390 Cr | ₹422 Cr | ₹415 Cr | ₹390 Cr | ₹308 Cr |
Profit After Tax | ₹361 Cr | ₹359 Cr | ₹328 Cr | ₹287 Cr | ₹311 Cr | ₹313 Cr | ₹290 Cr | ₹231 Cr |
EPS | ₹169.78 | ₹168.76 | ₹154.36 | ₹135.09 | ₹146.34 | ₹147.27 | ₹136.58 | ₹108.90 |
Industry Peers & Returns | 1W | 1M | 1Y |
ABBOTT INDIA | -2.5% | 1.2% | 14.9% |
SUN PHARMACEUTICAL INDUSTRIES | -3.9% | 3% | 7.9% |
DIVIS LABORATORIES | -5% | -1.1% | 71.6% |
CIPLA | -4.4% | 0.2% | -1.7% |
TORRENT PHARMACEUTICALS | -1.6% | 6.5% | 26.2% |
DR REDDYS LABORATORIES | -2.4% | 2.4% | -5.4% |
MANKIND PHARMA | 2.4% | 7.1% | 3.9% |
ZYDUS LIFESCIENCES | -3.3% | -1% | -11.4% |
LUPIN | -5.4% | 3.4% | 26.8% |
ABBOTT INDIA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -1.13 % |
Y-o-Y | 12.33 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2024 | ₹1,614 Cr | -1.13 | |
Sep2024 | ₹1,633 Cr | 4.82 | |
Jun2024 | ₹1,558 Cr | 8.27 | |
Mar2024 | ₹1,439 Cr | 0.10 | |
Dec2023 | ₹1,437 Cr | -3.81 | |
Sep2023 | ₹1,494 Cr | 1.02 | |
Jun2023 | ₹1,479 Cr | 10.12 | |
Mar2023 | ₹1,343 Cr | - |
ABBOTT INDIA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -0.65 % |
Y-o-Y | 12.48 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2024 | ₹436 Cr | -0.65 | |
Sep2024 | ₹439 Cr | 12.26 | |
Jun2024 | ₹391 Cr | 18.66 | |
Mar2024 | ₹330 Cr | -15.00 | |
Dec2023 | ₹388 Cr | 1.79 | |
Sep2023 | ₹381 Cr | 7.29 | |
Jun2023 | ₹355 Cr | 26.73 | |
Mar2023 | ₹280 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 0.45 % |
Y-o-Y | 0.11 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2024 | 27.01% | 0.45 | |
Sep2024 | 26.89% | 7.13 | |
Jun2024 | 25.1% | 9.56 | |
Mar2024 | 22.91% | -15.09 | |
Dec2023 | 26.98% | 5.85 | |
Sep2023 | 25.49% | 6.21 | |
Jun2023 | 24% | 15.05 | |
Mar2023 | 20.86% | - |
ABBOTT INDIA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 0.61 % |
Y-o-Y | 16.01 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2024 | ₹361 Cr | 0.61 | |
Sep2024 | ₹359 Cr | 9.33 | |
Jun2024 | ₹328 Cr | 14.27 | |
Mar2024 | ₹287 Cr | -7.69 | |
Dec2023 | ₹311 Cr | -0.63 | |
Sep2023 | ₹313 Cr | 7.82 | |
Jun2023 | ₹290 Cr | 25.42 | |
Mar2023 | ₹231 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 1.78 % |
Y-o-Y | 3.28 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2024 | 22.35 % | 1.78 | |
Sep2024 | 21.96 % | 4.27 | |
Jun2024 | 21.06 % | 5.56 | |
Mar2024 | 19.95 % | -7.81 | |
Dec2023 | 21.64 % | 3.34 | |
Sep2023 | 20.94 % | 6.73 | |
Jun2023 | 19.62 % | 13.87 | |
Mar2023 | 17.23 % | - |
ABBOTT INDIA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 0.60 % |
Y-o-Y | 16.02 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2024 | ₹169.78 | 0.60 | |
Sep2024 | ₹168.76 | 9.33 | |
Jun2024 | ₹154.36 | 14.26 | |
Mar2024 | ₹135.09 | -7.69 | |
Dec2023 | ₹146.34 | -0.63 | |
Sep2023 | ₹147.27 | 7.83 | |
Jun2023 | ₹136.58 | 25.42 | |
Mar2023 | ₹108.9 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD